(Bloomberg) — Short sellers in cannabis stocks are feeling the squeeze as Tilray Brands Inc. and Sundial Growers Inc. soared more than 55% each this week, and a House panel said it would vote next week for the second time to decriminalize marijuana.
Most Read from Bloomberg
Pot stocks, which have languished this year, also got a boost this week from deals in the sector and Senate passage of a bipartisan bill that would expand scientific and medical research on marijuana compounds. The global cannabis market’s growth hinges on legalization in the U.S. However, the glacial pace of federal legalization efforts in the U.S. has sowed doubts it will happen anytime soon.
Tilray and Sundial climbed to their highest levels since late last year on Friday, while U.S. shares of Canopy Growth Corp. and Aurora Cannabis Inc. both closed up 10%. Short sellers in these four stocks are down more than $360 million this week, according to S3 Partners data.
With bearish bets in these stocks mounting over the past month, “this short selling will not only wane as mark-to-market losses mount but shorts will be squeezed into reducing their short exposure,” said Ihor Dusaniwsky, a managing director at S3 who covers predictive analytics.
Two microcaps in the sector, HEXO Corp. and cbdMD Inc., could also feel the pinch, Dusaniwsky said in an interview.
ETFMG Alternative Harvest ETF, or MJ, the largest fund tracking the pot industry, advanced 15% this week.
© Bloomberg Shares of Tilray, Sundial surge on legislation hopes
Still, shorts may not be ready to close their bets just yet as analysts seemed less enthused by the developments, saying any decriminalization would run into obstacles in the Senate.
Video: Tailwinds will eventually come for cannabis stocks, says Canaccord Genuity’s Bottomley (CNBC)
Tailwinds will eventually come for cannabis stocks, says Canaccord Genuity’s Bottomley
What to watch next
CNBC Markets Now: March 25, 2022
CNBC
Post-Market Wrap: March 25, 2022
CNBC
CNBC TechCheck Evening Edition: March 25, 2022
CNBC
Cleveland-Cliffs isn’t a growth company, says Steve Weiss
CNBC
Tech and growth are the biggest portfolio risks right now, says Richard Bernstein’s Dan Suzuki
CNBC
Jim Cramer explains his bull case for ‘MANGO’ stocks
CNBC
Jim Cramer says the bear market is over
CNBC
The U.S. market is resilient despite the headwinds, says BMO’s Brian Belski
CNBC
2022 will be a year of divergence for retailers, says BMO Capital’s Simeon Siegel
CNBC
FedEx tests electric carts for delivery to reduce parking for trucks
CNBC
Evercore ISI’s Mark Mahaney discusses impact of new EU law targeting Big Tech
CNBC
Big Ten commissioner discusses how legal betting and NIL deals affect college sports
CNBC
RBC’s Helima Croft and Eurasia Group’s Ian Bremmer break down Europe-US energy deal
CNBC
Lawmakers should listen to constituents who want legal marijuana, says Tilray CEO Irwin Simon
CNBC
Frontier CEO Barry Biffle discusses how to balance surging travel demand with rising jet fuel costs
CNBC
‘We do need more infrastructure,’ in gas industry, says Chesapeake Energy CEO
CNBC
UP NEXT
“Cannabis legislation is not about the House or the White House. It is all about the Senate,” Cowen analyst Jaret Seiberg wrote in a note, saying that the House vote next week will be symbolic and should demonstrate how much GOP support cannabis legalization has in the chamber. Lesser measures targeting cannabis banking may have a somewhat better chance of passage, according to policy analysts.
It’s been an optimistic week for pot stocks. Two acquisition deals announced earlier in the week sparked the initial rally in the sector with Cresco Labs agreeing to buy Columbia Care for about $2 billion, and Aurora Cannabis’s purchase of TerraFarma Inc., owner of craft cultivator Thrive Cannabis.
While most marijuana stocks are still in the red this year, Tilray’s shares are now about 22% higher in 2022 and Sundial is up 40%.
(Updates with short interest, S3 commentary and shares throughout.)
Most Read from Bloomberg Businessweek
©2022 Bloomberg L.P.
Recent Comments